Antares Vision (Italy), OPTEL Vision (Canada) are Prominent Players in the Track and Trace Solutions Market

According to the new market research report “Track and Trace Solutions Market by Product (Plant Manager, Checkweigher, Barcode Scanner, Monitoring), Technology (2D Barcode, RFID), Application (Serialization, Aggregation, Reporting), End User (Pharma, Food, Medical Devices) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 7.3 billion by 2026 from USD 4.1 billion in 2021, at a CAGR of 12.1% during the forecast period.

Opportunities: Remote authentication of products;

Traditional brand protection technologies such as anti-theft and authentication are intended to protect individual items rather than safeguard the entire supply chain. There is a high possibility of fake products being introduced at any stage in the supply chain. To combat counterfeiting and identify massive product items, a solution with automatic and non-line-of-sight capabilities is required. The demand for technologies with modular designs, which fit enterprise needs, has increased in the last few years. For instance, track and trace technologies based on RFID maintain an electronic pedigree that records the transaction information of products within the supply chain. This approach proved to be a standout for protecting the supply chain against infiltration, theft, and fraud and supporting remote authentication in the brand protection supply chain. Technologies that are scalable from a single production line to a multi-facility/multi-line infrastructure while minimizing the initial investment are projected to gain attention in the coming future.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158898570

“The Software segment accounted for the largest market share in 2020.”

Based on products, the market is segmented into software, hardware components, and standalone platforms based on product. The software segment accounted for the largest share—60.1%—of the track and trace solutions market in 2020. Market growth is largely driven by the increasing awareness about secure packaging, the rising number of counterfeit drugs and related products, and growing awareness of brand protection. In addition, regulatory compliance is further supporting the growth of this market.

The standalone platforms segment is expected to register the highest CAGR of 15.9% during the forecast period. The growth in this market is mainly attributed to the stringent government regulations for implementing serialization and UDI codes in the pharma and medical device industry, increasing pressure on pharmaceutical companies to adopt serialization, and increasing demand for standalone platforms to reduce the serialization implementation timeframe.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=158898570

“The Serialization solutions segment accounted for the largest market share in 2020.”

Based on application, the track and trace solutions market is segmented into serialization solutions; aggregation solutions; and tracking, tracing, and reporting. The serialization solutions segment accounted for the largest share—62.3%—of the applications market. This segment is projected to grow at a CAGR of 12.0% during the forecast period to reach USD 2,560.9 million by 2026. Stringent regulations for the implementation of serialization solutions in packaging and supply chain applications drive this segments growth.

The tracking, tracing and reporting segment is expected to register the highest CAGR of 16.1% during the forecast period owing to the increasing number of regulations such as DSCSA, UDI, and Medical Device Reporting (MDR) for medical devices and pharmaceutical products.

“The 2D Barcode segment accounted for the largest market share in 2020.”

Based on technology, the track and trace solutions market is segmented into linear barcodes, 2D barcodes, and radiofrequency identification (RFID). The 2D barcodes segment accounted for the largest share of 76.2% of the technology market in 2020. This segment is projected to grow at a CAGR of 12.4% to reach USD 5,641.3 million by 2026. The large share of the 2D barcodes technology segment can be attributed to the increasing use of 2D barcodes in the packaging industry. They have higher data storage capacities than linear barcodes and contain larger amounts of data with fewer variations in image size.

The RFID segment is expected to register the highest CAGR of 13.7% during the forecast period due to the growing demand for these systems in automated pharmaceutical distribution and medical devices due to low labor costs and improved visibility & planning.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=158898570

“The Pharmaceutical and Biopharmaceutical Company segment accounted for the largest market share in 2020.”

Based on technology, the track and trace solutions market is segmented into linear barcodes, 2D barcodes, and radiofrequency identification (RFID). The 2D barcodes segment accounted for the largest share of 76.2% of the technology market in 2020. This segment is projected to grow at a CAGR of 12.4% to reach USD 5,641.3 million by 2026. The large share of the 2D barcodes technology segment can be attributed to the increasing use of 2D barcodes in the packaging industry. They have higher data storage capacities than linear barcodes and contain larger amounts of data with fewer variations in image size.

The RFID segment is expected to register the highest CAGR of 13.7% during the forecast period due to the growing demand for these systems in automated pharmaceutical distribution and medical devices due to low labor costs and improved visibility & planning.

“North America was the largest regional market for track and trace solutions market in 2020”

Geographically; divided into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 42.9% of the global market, followed by Europe (33.5%). The presence of developed healthcare systems in the US & Canada; the presence of many pharmaceutical & biotechnology companies and medical device manufacturers; stringent regulations regarding serialization; and the growing medical devices market are major factors driving market growth in North America.

Asia Pacific (APAC) is the fastest-growing market and is projected to grow at the highest CAGR of 13.8% for track and trace solutions. Growing regulatory requirements in the healthcare industry to comply with manufacturing and distribution practices, the rising number of pharmaceutical and biotechnology companies, and the significant economic development in emerging Asia Pacific countries such as China and India are the major factors driving the demand for track and trace solutions in the APAC region.

Some of the prominent players in the track and trace solutions market are OPTEL GROUP (Canada), Mettler-Toledo International Inc. (US), Systech International Inc. (US), TraceLink Inc. (US), Antares Vision (Italy), SAP (US), Xyntek Inc. (US), SEA Vision Srl (Italy), Syntegon (Germany), Körber Medipak Systems AG (Switzerland), Siemens AG (Germany), Uhlmann Group (Germany), JEKSON VISION (India), Videojet Technologies, Inc. (US), Zebra Technologies Corporation (US), Axway Inc. (US), ACG Worldwide (India), Laetus GmbH (Germany), and WIPOTEC-OCS (Germany).

Research Report on Dental Syringes Market Globally strategic overview

The Technological advancements in dental syringes, growth in geriatric population and government legislations to avoid needlestick injuries are adding to the growth prospects of this market.

Emerging markets (such as India, China, Brazil, and Mexico) offer significant growth opportunities for players operating in the dental syringes market. The growth of the market in these regions can be attributed to factors such as rising geriatric population, rising awareness among healthcare professionals related to needlestick injuries, and ongoing government initiatives to modernize & expand healthcare infrastructure.

Expected Revenue Surge: The Dental Syringes Market is expected to reach USD 126.9 Million, at a CAGR of 5.2% during the forecast period

Objectives of the Study;

• To define, describe, and forecast the global market on the basis of product, type, material, and region
• To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the global market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of the market with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=42523876

Market Segmentation in Detailed:

Based on Product;

Categorized into three segments, namely, non-disposable syringes, disposable syringes, and safety syringes. The non-disposable syringes segment is expected to dominate the dental syringes market in 2016 mainly due to the growing number of endodontic & periodontic procedures across the globe, significant adoption of non-disposable syringes among dental professionals for administering anesthesia, and greater affordability of these products due to their reusable nature.

Based on Type,

Segmented into two segments, namely, aspirating syringes, and non-aspirating syringes. The aspirating syringes segment is expected to dominate the dental syringes market during the forecast period. The prominent market position of the aspirating syringes segment can be primarily attributed to the procedural benefits offered by aspirating syringes over conventional syringes (such as easy syringe handling, minimal operational stress, and better operational control), and longer shelf life of metallic syringes (as compared to conventional plastic syringes).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42523876

Geographically;

Segmented into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period. The growth opportunities in the Asia-Pacific region can be attributed to the presence of a large patient population for target diseases (coupled with rapidly growing geriatric population, especially in Japan and China), rising awareness among healthcare professionals related to needlestick injuries, ongoing government initiatives to modernize & expand healthcare infrastructure, and continuous reduction in product prices.

Global Key Leaders:

Septodont (U.S.), 3M Company (U.S.), Dentsply International, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Vista Dental Products (U.S.), Power Dental USA, Inc. (U.S.), 4tek S.r.l (Italy), A. Titan Instrument Inc. (U.S.), and Delmaks Surgico (Pakistan) were some of the key players operating in the dental syringes market.

Women’s Health Care Market – Future Growth, Comprehensive Analysis & Key Players

The Womens HealthCare Market growth is primarily driven by factors such as the growing incidence of chronic health conditions among women, government initiatives to curb population growth, and growing demand for contraceptives to prevent unintended pregnancies. Moreover, the growing focus on R&D by key players for the development of advanced products is also a major factor in driving growth. The research study involved four major activities in estimating the current size of the global women’s healthcare market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Women’s HealthCare Market Size Estimation; Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. These methods were also used extensively to determine the size of various sub-segments in the market. The research methodology used to estimate the market size includes the following: – The key players in the industry and markets have been identified through extensive secondary research – The revenue generated from the sales of respective products from the respective geographies in the market by leading players were aggregated to get the market value for individual products at the global level. The global market values obtained for each product were added together to get the total global market value for the market. – All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136585329 Geographically; North America was the largest and the fastest-growing regional market for women’s healthcare. The increasing median age of first-time pregnancies and the growing prevalence of PCOS and postmenopausal osteoporosis are the factors responsible for the growth of this regional segment. Furthermore, the growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending also support the growth of this market. The prominent players in the global Women’s Health Care Market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US). Amgen (US) is one of the leading providers of the women’s healthcare market. The company’s sales and marketing activities are greatly focused on the US and Europe. The company provides Prolia and Xgeva for the treatment of osteoporosis in postmenopausal women. These drugs have shown a year-on-year double-digit value gain as well as volume growth, and constitute the largest share of the women’s healthcare market. Amgen’s EVENITY, meant for the treatment of osteoporosis in postmenopausal women, is also in phase 3 of development. It is being developed in collaboration with UCB (Belgium). The company’s high brand recognition and focus on product innovation have helped it to maintain its foothold in the market. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=136585329 Prolia is the largest and fastest-growing segment of the market. Based on drug, the women’s health care market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. Prolia has shown a considerable year-on-year growth primarily due to increasing unit demand. Prolia has witnessed positive market growth owing to the increasing prevalence of postmenopausal osteoporosis in the US.

Medical Gas Market Trends & Size is expected to grow in the Upcoming Years

The medical gas and equipment market has evolved significantly owing to various technological advancements. Factors such as increasing prevalence of chronic diseases, increasing incidence of respiratory diseases as a result of the high prevalence of tobacco use and rising pollution levels, rapid growth in the geriatric population, rising incidence of preterm births, and growing demand for home healthcare are expected to drive market growth in the coming years. Market expansion in emerging countries across APAC and technological advancements are also expected to present a wide range of opportunities.

Increasing prevalence of chronic diseases:

With changes in lifestyle and eating habits, the number of people suffering from obesity and related disorders across the globe has increased significantly in the last few years. The global prevalence of obesity nearly tripled between 1975 and 2016 According to the WHO, in 2016, more than 1.9 billion adults (18 years and older) were reportedly overweight, globally. Of these, over 650 million were found to be obese. Additionally, in 2016, ~340 million children and adolescents aged 5–19 were found to be overweight/obese across the globe.

Obesity is regarded as one of the major factors responsible for the increasing prevalence of chronic disorders, including heart disorders and diabetes. The WHO has stated that in the last two decades, there has been a significant increase in the prevalence of diabetes, heart diseases, and other non-communicable diseases, globally. According to the American Hospital Association, in 2015, ~149 million individuals in the US suffered from at least one chronic illness, such as hypertension, heart disease, and respiratory diseases. By 2030, this number is expected to reach 171 million. Since medical gases form a critical component of various long-term care treatments for several chronic conditions, including cardiovascular diseases, chronic respiratory diseases, and cancer, the rising prevalence of lifestyle diseases is expected to play a pivotal role in the growth of the medical gases and equipment market in the coming years.

Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=217979261

Medical Gas and Equipment Market

Growth Opportunity: Technological advancements;

Technological advancements have provided a growing range of functionality options for various medical gas handling equipment used in hospital care and home care. As opposed to earlier equipment, the latest technologically advanced equipment provides a complementary system of monitoring and therapy delivery, coupled with educational content and communication flow between patients and healthcare providers. In addition, currently, various associated medical gas equipment are gradually being improved to offer a better quality of care. The development of lightweight and portable medical gas handling equipment has emerged as a boon to the growing home healthcare market. Currently, several companies offering medical gas equipment are focusing on developing smaller and portable gas delivery systems that can be carried by patients.

Therapeutic segment will witness the highest growth in the market.

Based on application, the medical gases market is segmented into therapeutics, diagnostics, pharmaceutical manufacturing and research, and others. The therapeutic segment is expected to account for the largest share of the global medical gases and equipment market during the forecast period of 2018 to 2023. The large share of this segment can be attributed to rising incidences of cardiovascular diseases and increasing prevalence of respiratory disorders due to lifestyle changes, rising pollution levels, and growing smoking prevalance.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217979261

Geographical View in-detailed:

North America is expected to account for the largest share of the medical equipment market in 2018, followed by Europe and the Asia Pacific. The increasing adoption of technologically advanced medical gases and equipment products, growing ageing population, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, and the presence of a large number of leading medical gases and equipment manufacturers in the region, are responsible for the large share of the North American medical gas market.

Global Key Leaders:

The prominent players in the medical gas and equipment market include Air Products and Chemicals, Inc. (U.S.), The Linde Group (Germany), Taiyo Nippon Sanso Corp. (Japan), SOL-SpA (Italy), Air Liquide (France), Praxair, Inc. (U.S.), Atlas Copco (Sweden), Messer Group (Germany), and GCE Holding AB (Sweden)

Recent Developments:

– In 2018, Air Liquide acquired EOVE (France) to increase its presence in the home healthcare market. EOVE is a startup company specialized in the manufacturing of ventilators for home-based patients suffering from chronic respiratory failure.

– In 2018, GCE introduced MediVitop, a new One-Knob Cylinder Valve with Integrated Pressure Regulator.

– In 2018, Ceodeux Meditec launched ALPIFLOW, a next-generation flow meter with over ten years lifetime without additional maintenance. The product is attached directly to the Ceodeux Meditec ALPICONNECT or ALPINOX and MINIOX to regulate oxygen-flow from the hospital pipeline system and from portable oxygen cylinders.

Regenerative Medicine Market Research Report with Latest Trend, Share, Size, Opportunities For $ 17.9 billion Industry

The Regenerative Medicine Market growth is driven by rising investments in regenerative medicine research, and the growing pipeline of regenerative medicine products, and the increase in prevalence of chronic diseases, genetic disorders, and cancer.

Growing prevalence of chronic diseases, genetic disorders, and cancer;

Over the last few decades, the incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe. Diabetes and obesity can result in the increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, which require treatments and incur exorbitant medical expenses.

Opportunity: Implementation of the 21st Century Cures Act;

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation and covers various provisions that may impact the development and approval of several products in the coming years.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

Regenerative Medicine Market

The tissue-engineered products segment accounted for the largest share of the Regenerative Medicine Market.

Based on products, segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The tissue-engineered products segment accounted for the largest share in the market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment to register the highest growth rate during the forecast period

Based on applications, the Regenerative Medicine Market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579

Recent Developments:

– In February 2020, Integra Lifesciences (US) launched AmnioExcel Plus Placental allograft membrane.

– In November 2019, Stryker Corporation (US) acquired Wright Medical (US) to strengthen its product portfolio.

– In March 2019, Smith & Nephew (UK) acquired Osiris Therapeutics (US) to strengthen its product portfolio.

North America is the largest regional market for Regenerative Medicine Market

The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the market. The growth in the North American market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The major players operating in this Regenerative Medicine Market are 3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US).

Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=65442579

Point of Care Diagnostics Market – Growth Factors Analysis, Share and Forecast

The Point of Care Diagnostics Market growth of the global Point of Care diagnostics market can be attributed to factors such as increasing prevalence of respiratory diseases (such as COVID-19 and influenza) across the globe, and improved access to point-of-care devices through online platforms are some of the other key factors likely to drive the long-term growth.

High prevalence of infectious diseases:

The POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.

Listed below are important statistics related to major infectious diseases in developing countries:

• According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.|
  
• In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
  
• According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185

Point of Care & Rapid Diagnostics Market

The point of care diagnostics market includes major Tier I and II suppliers like the point-of-care diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Johnson & Johnson (US), Danaher Corporation (US), Chembio Diagnostics (US), Quidel Corporation. These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Demand for point of care diagnostics from key end-users has increased rapidly amidst the global COVID-19 pandemic. Industry experts believe that COVID-19 will have long erm increase in the growth for the point of care diagnostics market in 2020. Along with this, increase in prevalence of different types of infectious diseases, easy access of POC products through online platforms, and growing awaness about the low turnout time of diagnosis using rapid point of care test in turn will boost demnd for POC devices in the coming years.

Demand for glucose monitoring products for home use result in the segment occupying the high share of the point of care diagnostics market

Glucose monitoring products owes a good market share in point of care diagnostics market. The large share of this segment is attributed to factors such as the increase in the availability of glucose motioring devices increase in the prevalence of diabetes couples with growing collaborations among players for develop advance PoC deviceas and rapus shift towards the adoption of home helathacare products.

Asia Pacific likely to emerge as the fastest growing point of care diagnostics market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Japan and Singapore, are offering high-growth opportunities for market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. initiatives by the government,rising awareness about selftesting products, and increase in collaborations among key players in the point-of-care diagnostics market in the region. increasing number of hospitals in India and China; and rapid expansion of healthcare infrastructures,and increase in thenumber of research centers are driving the growth of the APAC point of care diagnostics market.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185

Prominent players in this market Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Becton Dickinson and Company (US), Abbott Laboratories (US), Quidel Diagnostics (US), and Chembio Diagnostics (US). Other prominent players operating in this market are EKF Diagnostics (UK), Trinity Biotech (Ireland), and Fluxergy (France).

Bone Growth Stimulator Market | Geographical Growth | Opportunities | Key Players

The Various factors such as the growing patient preference for non-invasive and minimally invasive surgical treatments, the rising prevalence of target conditions, and the growing number of sports and accident-related orthopedic injuries are the key factors driving the growth of the bone growth stimulators market. However, limited medical reimbursement for bone stimulation devices, high treatment costs associated with BMP and PRP products, and side effects associated with BMP-based orthopedic treatment are the key factors restraining the growth of bone growth stimulator market.

Growing patient preference for non-invasive and minimally invasive surgical treatments:

The demand for minimally invasive procedures has witnessed a significant increase owing to the advantages offered by these procedures over traditional treatment procedures. The key advantages of minimally invasive procedures include fewer operative complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infection, reduced postoperative care, and quicker recovery. Minimally invasive procedures make use of advanced technologies to diagnose and treat various diseases, including cancer. These procedures are used as an effective approach for removing cancer tumors and lymph nodes without scarring.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82341383

The bone growth stimulation devices segment to capture the largest share in the bone growth stimulator market, by product, during the forecast period.

The bone growth stimulation devices segment accounted for the largest share of the bone growth stimulators market in 2021. This can be attributed to the growing geriatric population, rising preference for non-surgical treatment procedures, and growing prevalence of nonunion fractures. Additionally, obesity, smoking, and diabetes, among other factors, can delay or inhibit bone healing after surgery or trauma. The rising incidence of these risk factors will further aid bone growth stimulator market growth.

The spinal fusion surgeries segment to witness the highest growth rate in the bone growth stimulator market.

Spinal fusion surgeries are conducted to connect two or more vertebrae permanently and eliminate motion between them. Bone growth stimulation products are used during or post surgeries to stimulate the natural bone growth process. The growth of this segment can be attributed to the growing geriatric population, the rising number of spine procedures, the established safety and efficacy of stimulators in fusion surgery, and the increasing use of bone growth stimulation products.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=82341383

Asia Pacific likely to emerge as the fastest-growing BGS market.

Emerging economies (such as China, India, Brazil, and Mexico) are expected to offer significant growth opportunities in the bone growth stimulators market. Factors such as the presence of a large patient population, rising healthcare expenditure, government initiatives to support the healthcare industry, strengthening export trade, and growing awareness among physicians, surgeons, and patients about the latest treatment options for spinal fusion and bone healing are expected to boost the demand for bone growth stimulation products in these countries. In addition, owing to the significant cost advantages, many patients from developed markets are reported to travel to these emerging markets to undergo medical treatment.

The prominent players operating in the global Bone Growth Stimulator Market include Orthofix Medical, Inc. (US), DJO Finance, LLC (US), Zimmer Biomet (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US), Terumo Corporation (Japan), Ember Therapeutics, Inc. (US), Ossatec Benelux Ltd. (Netherlands), Altis Biologics (Pty) Ltd. (South Africa), Regen Lab SA (Switzerland), ITO Co., Ltd. (Japan), Elizur Corporation (US), BTT Health GmbH (Germany), Stimulate Health Inc. (Canada), VQ OrthoCare (US), Kinex Medical Company, LLC (US), Fintek Bio-Electric Inc. (Canada), Biomedical Tissue Technologies Pty Ltd. (Germany), T-Biotechnology (Turkey), DrPRP America LLC (US), Ivy Sports Medicine, LLC (US), Glofinn Oy (Finland), and REMI GROUP (India) among others.

Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=82341383

Prefilled Syringes Market | Segmentation | Opportunities | Key Players

The growth in the prefilled syringes market is majorly driven by the rising demand for prefilled syringes is attributed to the growing prevalence of chronic diseases, technological advancements, rising adoption of self-injecting parenteral devices, and supportive government regulations (especially needlestick legislations). In addition, growing awareness on the benefits of prefilled syringes among patients and healthcare professionals, along with the growing number of biologics and biosimilars in the pharmaceuticals market, is supporting the growth of the prefilled syringes market.

Growing healthcare infrastructure across emerging markets:
Emerging countries continue to suffer from insufficient healthcare funding, which adversely affects access to healthcare, quality, and, ultimately, the health status of citizens. According to the World Bank, approximately 400 million people lack access to essential healthcare services, mostly in Africa and South Asia. Furthermore, accelerating medical inflation, i.e., the cost of medical treatments and a higher prevalence of non-communicable lifestyle-related diseases such as cancer, diabetes, or cardiac syndromes, have resulted in funding gaps.

According to a report published by Geneva Association, in the last two decades, the share of total aggregate global expenditure on healthcare in GDP has increased from about 8% to almost 10%, or an estimated USD 8 trillion per annum, which is driven by the accelerating cost of medical treatment, expanding treatment options and increasing customer demands. Moreover, the Global Burden of Disease Health Financing Collaborator Network (2017) estimates that global spending on health will almost triple to USD 24 trillion by 2040 with upper-middle-income countries are estimated to show the fastest increase at an average of 5.3% per year. This growth could be attributed to continued growth in GDP and the rise of the middle class and government spending.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=16618331

Leading Key Players and Analysis:

Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), and West Pharmaceutical Services, Inc. (US) are the key players in the global prefilled syringes market.

Gerresheimer (Germany) held the second position in the global syringes market, with a share of 13.3% in 2019. The company’s customer base includes a large number of global blue chip pharmaceutical and healthcare companies (Sanofi, Bayer, AstraZeneca, Novo Nordisk, Johnson & Johnson, and Novartis). To maintain its position in the market, the company focuses on the strategies of product launches and partnerships.

Geographical Analysis in Detailed?

Asia Pacific likely to emerge as the largest prefilled syringes market

Europe is one of the major revenue-generating regions in the market. Rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes. are the major factors driving the growth of the prefilled syringes market in Europe.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=16618331

Industry Segmentation:

Increasing adoption of self-administered injectable drugs is expected to result in the segment occupying the majority of the syringes market share

The conventional prefilled syringes market is estimated to have the largest market share by value. Growth of this segment can be attributed to the the advantages offered, such as safe administration, ease of use for both healthcare professionals and end users, reduced risk of contamination of the product, less waste of costly API, ease of manufacturing, improved dosing accuracy, and enhanced product differentiation when compared to vials is expected to drive the market growth

Plastic Prefilled Syringes estimated to be the fastest-growing market

Plastic prefilled syringes are estimated to be the fastest-growing segment in the prefilled syringes market. The growth of this segment can be attributed to the rising development of newer polymers (which possess various physical and chemical properties such as high heat & break resistance, tolerance of freeze-drying & liquid nitrogen exposure, high transparency, and solvent resistance.

Europe is estimated to be the largest market due to the rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes.

Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=16618331

Contract Research Organization Services Market – Developing Regions is Well-Positioned for Strong Growth in the Coming Years

The Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0 % during the forecast period.

Increasing investment in pharmaceutical R&D:

Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharmaceutical companies are increasing their R&D efficiencies through heavy investments in R&D and through collaborative R&D efforts. According to the EvaluatePharma report, the global pharmaceutical R&D spending was valued at USD 137 billion in 2012; this increased to USD 212 billion in 2021 and is projected to reach USD 254 billion by 2026. As per the report, R&D spending is observed to be growing steadily at a CAGR of 4.2% from 2020 to 2026. This is expected to boost the outsourcing of research services by pharmaceutical companies, biotechnology companies, as well as research and academic organizations.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167410116

Contract Research Organization (CROs) Services Market

Growth in the drugs and biologics market despite the COVID-19 pandemic:

Despite the ongoing COVID-19 pandemic, 2020 has been the second-best year for the pharmaceutical industry in terms of the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 comprised 40 new chemical entities and 13 biologics. The approved biologics included 10 monoclonal antibodies, 2 antibody-drug conjugates, 3 peptides, and 2 oligonucleotides. The FDA has authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010. This growth in the number of approved products worldwide is attributed to the rising investments by biopharmaceutical companies to develop biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical product sales in 2022.

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021.

Based on type, the Contract Research Organization Services Market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.  

The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021. 

Based on therapeutic area, the Contract Research Organization (CROs) Services Market is segmented into oncology, infectious diseases, neurology, vaccines, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the global Contract Research Organization Services Market in 2021. The large share of this segment is primarily attributed to the increasing number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.

Request Sample Pages: 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=167410116

The Asia Pacific region is the fastest-growing region of the CRO services market in 2021.

Based on the region The global Contract Research Organization (CROs) Services Market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The market in the Asia Pacific is estimated to record the highest CAGR during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, increasing number of pharmaceutical companies establishing their manufacturing facilities in the region, and the lower cost of clinical trials in the region.

Key players in the Contract Research Organization Services Market include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (Now a part of Thermo Fisher Scientific Inc.) (US), ICON plc (Ireland), Syneos Health, Inc. (US), Parexel International Corporation (US), and Charles River Laboratories International Inc. (US)

Speak to Analyst: 
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=167410116

Growth Strategies Adopted by Key Players in the Global Lateral Flow Assays Market

According to the new market research report “Lateral Flow Assays Market by Application (Clinical Testing (Pregnancy, Infectious Diseases (Mosquito, Influenza, STI, Hepatitis, TB) Cardiac Marker Lipid Test) Veterinary, Food Safety), Product, Technique, End User – Global Forecast to 2025″, published by MarketsandMarkets™.

DRIVERS: High prevalence of infectious disease across the globe;

Despite significant improvements in sanitation and medicine, the global prevalence of infectious diseases is still high. Although non-communicable diseases are the leading cause of morbidity and mortality, infectious diseases remain a major public health concern across the globe. The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries.

The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries. In addition, recent outbreaks of infectious diseases from the spread of viruses (such as Ebola, H1N1, and Zika) have highlighted the need for early disease detection capabilities, which is also expected to drive market growth. The current COVID-19 pandemic has resulted in high demand for rapid diagnostic testing through lateral flow technology, supporting the growth of this market in the coming year.

Rapidly increasing geriatric population;

Age-related physiological changes and metabolic inefficiencies often result in chronic diseases such as cystic fibrosis, hepatitis, cardiovascular disorders, and cancer. Geriatric individuals (65 years and above) are more susceptible to these diseases and infectious diseases due to weakened immune systems. With the growing prevalence of chronic diseases, the emphasis on the effective and early diagnosis of diseases is rising. Lateral flow assay techniques are increasingly preferred for disease diagnosis due to their ability to detect symptoms in the early stages. The global rise in the geriatric population, coupled with the increasing patient pool for chronic diseases, translates into higher demand for lateral flow assay tests.

Furthermore, age-caused frailty has been an important concern during COVID-19 management. The risk of death from COVID-19 increases with both age and the presence of co-morbidities such as cardiovascular, pulmonary, or kidney disease, cancer, and obesity.

With the growing prevalence of chronic diseases, the emphasis on the effective and early diagnosis of diseases is rising. Lateral flow assay techniques are increasingly preferred for disease diagnosis due to their ability to detect symptoms in the early stages. The global rise in the geriatric population, coupled with the increasing patient pool for chronic diseases, translates into higher demand for lateral flow assay tests.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133

Lateral Flow Assays Market

The high prevalence of infectious diseases worldwide, rapid growth in the geriatric population, growing demand for point-of-care testing, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. However, other reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key factors restraining the growth of the market.

Evolving application of lateral flow assays:

Lateral flow assays have evolved rapidly in the last two decades and are routinely used in POC and diagnostic applications. Although lateral flow tests are widely being used for infectious disease diagnostics, the diagnosis of cardiac diseases, and veterinary applications, their use has increased in several new applications over the last few years. For instance, saliva diagnostics, behavioral health, agriculture (genetically modified organism detection and crop quality testing), biowarfare (anthrax detection), environmental testing (detection of contaminating enzymes in manufacturing plants), and food microbiology (detection of E. coli O157, Salmonella, Listeria, and other food spoilage organisms) have emerged as new application areas for lateral flow assays.

OraSure Technologies (US) is one of the major providers of lateral flow saliva testing. Salivary LFIAs have also penetrated the market for applications such as drugs-of-abuse testing, and several systems have been FDA-cleared for marketing; however, testing remains largely qualitative.

Salivary rapid tests have also been developed for infectious diseases. Companies such as SOMA Bioscience (UK) have developed quantitative saliva LFIAs for IgG, IgA, α-amylase, and cortisol; SOMA Bioscience’s salivary cortisol LFDs have been used in sports research. Medusa 19 Limited (UK) has developed the Rapid Saliva Protein Test (“RSPT”), which is a lateral flow saliva test to indicate the immune response to SARS-CoV-2 infection.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133

North America to dominate the Lateral Flow Assays market during the forecast period

North America is expected to account for the largest share of the Lateral Flow Assay market in 2019, followed by Europe. The dominance of the North American region can be attributed to, increasing R&D investment in the region and presence of a large number of market players.

Prominent players in the Lateral Flow Assaysmarket include Abbott Laboratories (US), F.Hoffman La-Roche Ltd. (Switzerland), Danaher Corporation(US), Becton, Dickinson, and Company (US), Siemens AG (Germany) &Thermofisher Scientific (US)

Virology Specimen Collection Market – Emerging Industry Trends and Global Future Forecast

The Growth in Virology Specimen Collection Market is mainly driven by the rising prevalence of viral diseases, the increasing prevalence of human papillomavirus (HPV) and cervical cancer, and the growing number of blood donations.

Rising prevalence of viral diseases and emergence of newer pathogens:

The Zika virus and Babesia outbreaks, alongside announcements for their inclusion in virology specimen collection tests, indicate the need for innovation in virology specimen collection technologies, consumables, and instruments. Other countries have also undertaken initiatives to check for new and emerging diseases. For example, the prevalence of malaria in African regions and the possibility of mosquito-borne transfer of Zika has resulted in mandates for Zika virus screening in the region.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150226807

This research study involved four major activities in estimating the current size of the virology specimen collection market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

The viral transport media segment accounted for the largest share of the specimen collection market, by product segment, in 2020

Based on product, the virology specimen collection market is segmented into blood collection kits, specimen collection tubes, viral transport media and swabs. The viral transport media segment accounted for the largest share of the market in 2020. Factors such as rising prevalence of viral diseases and emergence of newer pathogens are contributing for the growth of this market.

Blood segment to register the highest growth rate during the forecast period

The virology specimen collection market is segmented into blood, nasopharyngeal, nasal, throat, cervical, oral and other samples. In 2020, the blood segment accounted for the highest growth rate. Factors such as the rising number of blood donations and rising prevalence of viral diseases and emergence of newer pathogens.

Request Sample Pages: 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150226807

Geographically: The global Virology Specimen Collection Market is segmented into four major regions, namely, North America, Europe, the Asia Pacific and Rest of the World. In 2020, North America accounted for the largest share of the market. The large share of this region can be attributed to increasing number of blood donations in the region.

The major players operating in virology specimen collection market are Becton, Dickinson and Company (US), Quidel Corporation (US), Thermo Fisher Scientific, Inc. (US), Trinity Biotech (Ireland), Titan Biotech, Ltd. (India), Diasorin SA (Italy), Vircell S.L. (Spain), Copan Italia S.p.A. (Italy), Puritan Medical Products, Co. (Guilford, ME) and Hardy Diagnostics (US).

Speak to Analyst: 
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=150226807

In Vivo Toxicology Market future growth probabilities and Comprehensive Analysis & Key Players are Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp)

Growth Factors Driving the Market: The In Vivo Toxicology Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine

Rising demand for humanized animal models:

Humanized animal models are important tools for conducting preclinical research to gain insights into human biology. These models are developed through the engraftment of human cells or tissues, leading to the expression of human proteins in animals.

Humanized mice are increasingly being used as models for biomedical research applications, such as cancer, infectious diseases, HIV/AIDS, regenerative medicine, and hepatitis. In March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the US Department of Health and Human Services, announced funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The need to identify the actual effects of drugs on humans, as well as the growing focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized animal models

The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811

Industry Segmentation in Detailed:

Based on toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment

Based on test type, the global in vivo toxicology testing market is segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.

Based on the testing facility, the global in vivo toxicology market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to dominate the market, by testing facility, over the forecast period. In 2019, the outsourced testing facilities segment held the largest share of the global in vivo toxicology market. The large share of this segment is attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, resulting in increased outsourcing of services to CROs

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=105308811

Leading Key Players Analysis:

The major players operating in In Vivo Toxicology Testing Market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.

Geographical Trends in Detailed:

The global in vivo toxicology market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811